IGM Biosciences, Inc. financial data

Symbol
IGMS on Nasdaq
Industry
Pharmaceutical Preparations
Location
325 E Middlefield Road, Mountain View, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Palingen, Inc. (to 7/16/2010)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 816 % -15.2%
Debt-to-equity 117 % +47.8%
Return On Equity -119 % -41.4%
Return On Assets -54.7 % -16.7%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 132M USD -39.7%
Weighted Average Number of Shares Outstanding, Basic 60.4M shares +33.9%
Weighted Average Number of Shares Outstanding, Diluted 60.4M shares +33.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 195M USD -2.52%
General and Administrative Expense 45.3M USD -9.94%
Operating Income (Loss) -237M USD +4.54%
Nonoperating Income (Expense) 17.2M USD +20.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -220M USD +6.08%
Income Tax Expense (Benefit) 482K USD +146%
Net Income (Loss) Attributable to Parent -220M USD +5.95%
Earnings Per Share, Basic -3.57 USD/shares +31.6%
Earnings Per Share, Diluted -3.57 USD/shares +31.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67M USD -55.6%
Marketable Securities, Current 236M USD -19.1%
Assets, Current 266M USD -33.8%
Property, Plant and Equipment, Net 36M USD -6.14%
Operating Lease, Right-of-Use Asset 33M USD -14%
Other Assets, Noncurrent 1.43M USD -32.5%
Assets 337M USD -30%
Accounts Payable, Current 3.26M USD -34%
Accrued Liabilities, Current 26.5M USD -4.6%
Liabilities, Current 37.7M USD -15%
Operating Lease, Liability, Noncurrent 33.4M USD -3.19%
Liabilities 214M USD -3.56%
Accumulated Other Comprehensive Income (Loss), Net of Tax -195K USD +56.9%
Retained Earnings (Accumulated Deficit) -919M USD -31.6%
Stockholders' Equity Attributable to Parent 122M USD -52.7%
Liabilities and Equity 337M USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42.4M USD +16.8%
Net Cash Provided by (Used in) Financing Activities 152K USD +103%
Net Cash Provided by (Used in) Investing Activities 8.65M USD -87.6%
Common Stock, Shares Authorized 120M shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -33.6M USD -278%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 67.3M USD -55.6%
Deferred Tax Assets, Valuation Allowance 267M USD +41.4%
Deferred Tax Assets, Gross 280M USD +39.4%
Operating Lease, Liability 40.5M USD -1.62%
Depreciation 2.18M USD +30.8%
Payments to Acquire Property, Plant, and Equipment 2.48M USD -36.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -220M USD +6.06%
Lessee, Operating Lease, Liability, to be Paid 55.2M USD -10.4%
Property, Plant and Equipment, Gross 58.8M USD +28.4%
Operating Lease, Liability, Current 5.94M USD -13.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.1M USD -17.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.89M USD +14.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.3M USD -18.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.21M USD +1.72%
Deferred Tax Assets, Operating Loss Carryforwards 73.4M USD -8.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 10.6M USD +52.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.38M USD +2.74%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%